Search research articles
Contact Us
Filters
Showing results (11-20 of 23) with videos related to
Page
of 3
Sort By:
Lancet (London, England)
|
October 27, 2018
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter, Peter J Goadsby, Michel Lanteri-Minet, et al.
Therapeutic Innovation & Regulatory Science
|
May 4, 2024
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective
Daniel Li, Zhenzhen Xu, Shihua Wen, et al.
European Journal of Gastroenterology & Hepatology
|
April 14, 2020
Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure
Dabiao Chen, Shihua Wen, Zebin Wu, et al.
Cephalalgia : an International Journal of Headache
|
November 8, 2021
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial
Uwe Reuter, Marc Ehrlich, Astrid Gendolla, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 30, 2021
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, et al.
Neurology
|
April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study
Peter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
The Journal of Headache and Pain
|
November 20, 2022
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
Shengyuan Yu, Byung-Kun Kim, Hebo Wang, et al.
Neurology
|
April 26, 2024
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study
Uwe Reuter, Peter J Goadsby, Michel D Ferrari, et al.
Headache
|
May 24, 2024
Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
Shuu-Jiun Wang, Byung-Kun Kim, Hebo Wang, et al.
Cephalalgia : an International Journal of Headache
|
December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Jan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 23) with videos related to
Sort By:
Page
of 3
Lancet (London, England)
|
October 27, 2018
Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study
Uwe Reuter, Peter J Goadsby, Michel Lanteri-Minet, et al.
Therapeutic Innovation & Regulatory Science
|
May 4, 2024
Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective
Daniel Li, Zhenzhen Xu, Shihua Wen, et al.
European Journal of Gastroenterology & Hepatology
|
April 14, 2020
Association between effective hepatic blood flow and the severity and prognosis of hepatitis B virus-related acute on chronic liver failure
Dabiao Chen, Shihua Wen, Zebin Wu, et al.
Cephalalgia : an International Journal of Headache
|
November 8, 2021
Erenumab versus topiramate for the prevention of migraine - a randomised, double-blind, active-controlled phase 4 trial
Uwe Reuter, Marc Ehrlich, Astrid Gendolla, et al.
Journal of Neurology, Neurosurgery, and Psychiatry
|
November 30, 2021
Two-year efficacy and safety of erenumab in participants with episodic migraine and 2-4 prior preventive treatment failures: results from the LIBERTY study
Michel Dominique Ferrari, Uwe Reuter, Peter J Goadsby, et al.
Neurology
|
April 29, 2021
Long-term Efficacy and Safety of Erenumab: Results From 64 Weeks of the LIBERTY Study
Peter J Goadsby, Uwe Reuter, Michel Lanteri-Minet, et al.
The Journal of Headache and Pain
|
November 20, 2022
A phase 3, randomised, placebo-controlled study of erenumab for the prevention of chronic migraine in patients from Asia: the DRAGON study
Shengyuan Yu, Byung-Kun Kim, Hebo Wang, et al.
Neurology
|
April 26, 2024
Efficacy and Safety of Erenumab in Participants With Episodic Migraine in Whom 2-4 Prior Preventive Treatments Had Failed: LIBERTY 3-Year Study
Uwe Reuter, Peter J Goadsby, Michel D Ferrari, et al.
Headache
|
May 24, 2024
Effect of erenumab on the reversion from chronic migraine to episodic migraine in an Asian population: A post hoc analysis of the DRAGON study
Shuu-Jiun Wang, Byung-Kun Kim, Hebo Wang, et al.
Cephalalgia : an International Journal of Headache
|
December 10, 2019
The spectrum of response to erenumab in patients with chronic migraine and subgroup analysis of patients achieving ≥50%, ≥75%, and 100% response
Jan Lewis Brandes, Hans-Christoph Diener, David Dolezil, et al.
Page
of 3